VIOL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,670 KRW | +3.59% |
|
+1.52% | +25.53% |
| Mar. 25 | Sihuan Pharmaceutical's RF Device Wins Registration Approval in China | MT |
| 2023 | SULLIVAN WILL DISCUSS EFFORTS TO REIN IN 'EXTREMIST SETTLER VIOL… | RE |
| Sales 2023 | 42.52B 30.7M | Sales 2024 * | 61.46B 44.37M | Capitalization | 616B 445M |
|---|---|---|---|---|---|
| Net income 2023 | 21B 15.16M | Net income 2024 * | 29B 20.94M | EV / Sales 2023 | 11.5 x |
| Net cash position 2023 * | 50.98B 36.8M | Net cash position 2024 * | 75.36B 54.41M | EV / Sales 2024 * | 8.8 x |
| P/E ratio 2023 |
23
x | P/E ratio 2024 * |
20.9
x | Employees | 54 |
| Yield 2023 * |
0.09% | Yield 2024 * |
0.21% | Free-Float | 61.92% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +3.59% | ||
| 1 week | +1.52% | ||
| 1 month | +5.85% | ||
| 3 months | +45.77% | ||
| 6 months | +17.77% | ||
| Current year | +25.53% |
1 week
10 270.00
11 010.00
1 month
9 520.0011 770.00
Current year
7 050.0012 030.00
1 year
5 900.0012 030.00
3 years
1 635.0012 030.00
5 years
1 635.0012 030.00
10 years
1 635.0012 030.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Jin Lee
CEO | Chief Executive Officer | 55 | - |
Jong-Ju Ra
CTO | Chief Tech/Sci/R&D Officer | 55 | - |
Seong-Jong Jo
AUD | Comptroller/Controller/Auditor | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Seok Park
BRD | Director/Board Member | 65 | - |
Sang-Jin Lee
CEO | Chief Executive Officer | 55 | - |
Dong-Seok Gwak
BRD | Director/Board Member | 55 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 10,670 | +3.59% | 1,929,797 |
| 24-05-30 | 10,300 | -1.90% | 1,200,943 |
| 24-05-29 | 10,500 | -3.49% | 1,557,144 |
| 24-05-28 | 10,880 | +2.93% | 2,299,287 |
| 24-05-27 | 10,570 | +0.57% | 1,113,296 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
Viol Co Ltd, formerly IBKS No.11 Special Purpose Acquisition Co, is a Korea-based company mainly engaged in the manufacture and sale of medical devices for skin beauty. The Company's main product is Scarlet, an equipment for elasticity and lifting. In addition, the Company develops and produces medical devices for anti-aging skin care. The Company sells its products in domestic and overseas markets such as China and the United States.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
10,670
KRW
Average target price
13,800
KRW
Spread / Average Target
+29.33%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +25.53% | 446M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
- Stock Market
- Equities
- A335890 Stock
